Suppr超能文献

血清严重急性呼吸综合征冠状病毒 2 核糖核酸作为 2019 年冠状病毒病严重结局的预测因子:一项回顾性队列研究。

Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Serum as Predictor of Severe Outcome in Coronavirus Disease 2019: A Retrospective Cohort Study.

机构信息

Department of Infectious Diseases, Danderyd Hospital, Stockholm, Sweden.

Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.

出版信息

Clin Infect Dis. 2021 Nov 2;73(9):e2995-e3001. doi: 10.1093/cid/ciaa1285.

Abstract

BACKGROUND

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). This study aimed to determine if SARS-CoV-2 RNA in serum at admission correlated with clinical outcome in COVID-19.

METHODS

COVID-19 patients admitted to the infectious diseases department of a tertiary level Swedish hospital and sampled for SARS-CoV-2 RNA in serum at admission during 10 April to 30 June 2020 were included. Primary outcomes were day 28 all-cause mortality and progress to critical disease.

RESULTS

The cohort (N = 167) consisted of 106 SARS-CoV-2 RNA serum-negative and 61 serum-positive patients. Median sampling time for initial SARS-CoV-2 in serum was 1 day (interquartile range [IQR], 1-2 days) after admission, corresponding to day 10 (IQR, 8-12) after symptom onset. Median age was 53 years (IQR, 44-67 years) and 63 years (IQR, 52-74 years) for the serum-negative and -positive patients, respectively. In the serum-negative and -positive groups, 3 of 106 and 15 of 61 patients died, respectively.The hazard ratios for critical disease and all-cause mortality were 7.2 (95% confidence interval [CI], 3.0-17) and 8.6 (95% CI, 2.4-30), respectively, for patients with serum-positive compared to serum-negative results.

CONCLUSIONS

SARS-CoV-2 RNA in serum at hospital admission indicates a high risk of progression to critical disease and death.

摘要

背景

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起 2019 年冠状病毒病(COVID-19)。本研究旨在确定入院时血清中的 SARS-CoV-2 RNA 是否与 COVID-19 的临床结局相关。

方法

纳入 2020 年 4 月 10 日至 6 月 30 日期间在瑞典一家三级医院传染病科入院并采集血清中 SARS-CoV-2 RNA 的 COVID-19 患者。主要结局为 28 天全因死亡率和进展为危重症疾病。

结果

队列(N=167)包括 106 例 SARS-CoV-2 RNA 血清阴性和 61 例血清阳性患者。初次血清 SARS-CoV-2 样本采集时间中位数为入院后 1 天(四分位距 [IQR],1-2 天),相当于症状出现后第 10 天(IQR,8-12 天)。中位年龄分别为 53 岁(IQR,44-67 岁)和 63 岁(IQR,52-74 岁),分别为血清阴性和阳性患者。血清阴性和阳性组中,分别有 3/106 和 15/61 例患者死亡。与血清阴性结果相比,血清阳性患者发生危重症和全因死亡的风险比分别为 7.2(95%置信区间 [CI],3.0-17)和 8.6(95% CI,2.4-30)。

结论

入院时血清中的 SARS-CoV-2 RNA 表明进展为危重症疾病和死亡的风险较高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f67e/8563198/3efdb818b33a/ciaa1285f0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验